Combined analysis with Bcl-2 and P53 immunostaining predicts poorer prognosis in prostatic carcinoma.

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Journal of Urology

• Publication date

  1997-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0022-5347(01)68235-1PMID 9366376
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Immunohistochemical analysis of bcl-2 and p53 expression in breast carcinomas: their correlation with Ki-67 growth fraction

  2004cited by this paper
• bcl-2: role in epithelial differentiation and oncogenesis.

  1996cited by this paper
• Inverse correlation between the expression of bcl-2 and p53 proteins in primary gastric lymphoma.

  1996cited by this paper
• Prognostic value of Bcl-2 and p53 expression in urinary tract transitional cell cancer.

  1996cited by this paper
• bcl‐2 Expression in Prostate Cancer and its Relationship to Cell Cycle and Prognosis

  1996cited by this paper
• Prognostic significance of Bcl-2 in clinically localized prostate cancer.

  1996cited by this paper
• Relationship of p53 and bcl-2 to prognosis in muscle-invasive transitional cell carcinoma of the bladder.

  1996cited by this paper
• bl-2 [corrected] Expression on prostate cancer and its relationship to cell cycle and prognosis.

  1996cited by this paper
• Prognostic value of bcl-2 immunoreactivity in medullary thyroid carcinoma.

  1995cited by this paper
• Immunohistochemical detection of p53 protein as a prognostic indicator in prostate cancer.

  1995cited by this paper
• Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo.

  1995cited by this paper
• p53 Mutations Occur in Clinical, but Not Latent, Human Prostate Carcinoma

  1995cited by this paper
• p53 nuclear protein expression is an independent prognostic marker in clinically localized prostate cancer patients undergoing radical prostatectomy.

  1995cited by this paper
• Association of p53 mutations with metastatic prostate cancer.

  1995cited by this paper
• Bcl‐2 protein expression in carcinomas originating from the follicular epithelium of the thyroid gland

  1994cited by this paper
• Down-regulation of bcl-2 by p53 in breast cancer cells.

  1994cited by this paper
• Bcl-2 protein expression and long-term survival in breast cancer.

  1994cited by this paper
• Association of p53 immunoreactivity with high gleason tumor grade in prostatic adenocarcinoma.

  1994cited by this paper
• Bcl-2 immunoreactivity in breast carcinoma correlates with hormone receptor positivity.

  1994cited by this paper
• Frequency and characterization of p53 mutations in primary and metastatic human prostate cancer

  1994cited by this paper
• Expression of the apoptosis-suppressing protein bcl-2, in neuroblastoma is associated with unfavorable histology and N-myc amplification.

  1993cited by this paper
• p53 protein immunostaining in routinely processed paraffin-embedded sections.

  1993cited by this paper
• p53 protein accumulation and gene mutation in the progression of human prostate carcinoma.

  1993cited by this paper
• Detection of the apoptosis-suppressing oncoprotein bc1-2 in hormone-refractory human prostate cancers.

  1993cited by this paper
• High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy.

  1993cited by this paper
• p53 is mutated in a subset of advanced-stage prostate cancers.

  1993cited by this paper
• Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation.

  1992cited by this paper
• Markers of the metastatic phenotype in prostate cancer.

  1992cited by this paper
• Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer.

  1992cited by this paper
• Nucleotide sequence of a t(14;18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint-cluster region near a transcriptionally active locus on chromosome 18.

  1985cited by this paper
• The t(14;18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining.

  1985cited by this paper

• Effects of Brassicaceae Isothiocyanates on Prostate Cancer

  2016cites this paper
• Expression of CD95 in Acute Lymphocytic Leukemia (ALL) in Egyptian Children before and after Treatment

  2015cites this paper
• Apoptosis and Autophagy

  2013cites this paper
• Difference in Protein Expression Profile and Chemotherapy Drugs Response of Different Progression Stages of LNCaP Sublines and Other Human Prostate Cancer Cells

  2013cites this paper
• Molecular Targets for Radiation Oncology in Prostate Cancer

  2011cites this paper
• Dual targeting of Bcl-2 and VEGF: a potential strategy to improve therapy for prostate cancer.

  2011cites this paper
• Role of immunohistochemistry and apoptosis as investigative tools in assessing the prognosis of patients with prostate tumours.

  2010cites this paper
• Relationship between apoptosis regulator proteins (bcl-2 and p53) and Gleason score in prostate cancer

  2009cites this paper
• Effects of CXCR4 antagonist CTCE‐9908 on prostate tumor growth

  2009cites this paper
• Grade-dependent effects on cell cycle progression and apoptosis in response to doxorubicin in human bladder cancer cell lines.

  2009cites this paper
• Molecular and prognostic markers in prostate cancer

  2008cites this paper
• The emergence of DNA methylation as a key modulator of aberrant cell death in prostate cancer.

  2008cites this paper
• p53 antibodies in the serum of patients with prostate cancer

  2007cites this paper
• Perfil imunohistoquímico das proteínas da família BCL-2 e evolução clínica do câncer de ovário : uma análise de pacientes do Hospital de Clínicas de Porto Alegre/Brasil (1996 a 2004)

  2007cites this paper
• Potential applications of designed ankyrin repeat proteins in diagnostics and therapeutics.

  2007cites this paper
• Absence of Bcl‐2 expression favors response to the short‐term administration of diethylstilbestrol diphosphate in prostate Cancer

  2006cites this paper
• Evolving treatment paradigms for locally advanced and metastatic prostate cancer

  2006cites this paper
• Apoptosis in prostate cancer: Bax correlation with stage

  2005cites this paper
• Immunohistochemical expression of Bcl2 is an independent predictor of time-to-biochemical failure in patients with clinically localized prostate cancer following radical prostatectomy.

  2005cites this paper
• Promoting apoptosis as a strategy for cancer drug discovery

  2005cites this paper
• Oncogenes and Tumor Suppressor Genes in Prostate Cancer 37 CHROMOSOMAL ABNORMALITIES IN PROSTATE CANCER CELLS

  2005cites this paper
• Correlation of p53 protein accumulation and Bcl-2 overexpression with histopathological features in prostatic cancer.

  2005cites this paper
• Promoting apoptosis as a strategy for cancer drug discovery

  2005cites this paper
• Immunohistochemical expression of Ki-67 antigen, cox-2 and Bax/Bcl-2 in prostate cancer; prognostic value in biopsies and radical prostatectomy specimens.

  2005cites this paper
• The role of HER2/neu, BCL2, p53 genes and proliferating cell nuclear protein as molecular prognostic parameters in localized prostate carcinoma

  2004cites this paper
• Apoptosis in prostate cancer: progressive and therapeutic implications (Review).

  2004cites this paper
• Immunopathological prognostic and predictive factors in prostate cancer

  2004influential citation
• p53 Protein Expression and Its Relation to the Apoptotic Index in Prostate Adenocarcinoma

  2004cites this paper
• Prostate Cancer

  2003influential citation
• Molecular markers of outcome after radiotherapy in patients with prostate carcinoma

  2003cites this paper
• Preoperative Staging of Prostate Cancer: The Role of Molecular Markers

  2003cites this paper
• Limitations of tissue microarrays in the evaluation of focal alterations of bcl-2 and p53 in whole mount derived prostate tissues.

  2003cites this paper
• The role of p53, bcl-2 and E-cadherin expression in predicting biochemical relapse for organ confined prostate cancer in Taiwan.

  2003cites this paper
• Aspectos clínicos de la biología molecular del cáncer de próstata

  2002cites this paper
• Phosphorylation of Fas‐associated Death Domain Contributes to Enhancement of Etoposide‐induced Apoptosis in Prostate Cancer Cells

  2002cites this paper
• Molecular markers in prostate cancer: the role in preoperative staging.

  2002cites this paper
• P53 gene mutations: case study of a clinical marker for solid tumors.

  2002cites this paper
• Apoptosis and bcl-2 expression in prostate cancer: significance in clinical outcome after brachytherapy.

  2001cites this paper
• Relationship of p21WAF‐I protein expression with prognosis in advanced prostate cancer treated by androgen ablation

  2001cites this paper
• Oncogenes and tumor suppressor genes in prostate cancer.

  2001cites this paper
• The role of imaging studies and molecular markers for selecting candidates for radical prostatectomy.

  2001cites this paper
• Abnormal Expression of MDM2 in Prostate Carcinoma

  2001cites this paper
• A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential.

  2001cites this paper
• Antisense anticancer oligonucleotide therapeutics.

  2001cites this paper
• Apoptotic pathways in prostate cancer

  2001cites this paper
• Evaluation of p53, bcl-2 Proteins and DNA Ploidy in Squamous and Transitional Cell Carcinomas of Urinary Bladder

  2001cites this paper
• Prognostic Significance of Ki–67 Expression in Advanced Prostate Cancers in Relation to Disease Progression after Androgen Ablation

  2000cites this paper
• Molecular genetics of prostate cancer.

  2000cites this paper
• Novel Fatty Acid Lipoxygenases in the Development of Human and Murine Prostate Cancer

  2000cites this paper
• Outcome prediction with p53 immunostaining after radical prostatectomy in patients with locally advanced prostate cancer.

  2000cites this paper
• Bcl-2 and p53 protein expression, apoptosis, and p53 mutation in human epithelial ovarian cancers.

  2000cites this paper
• Monoclonal antibodies.

  2000cites this paper
• Molecular markers for predicting prostate cancer stage and survival

  2000cites this paper
• p53 accumulation associated with bcl-2, the proliferation marker MIB-1 and survival in patients with prostate cancer subjected to watchful waiting.

  2000cites this paper
• Low apoptotic activity in primary prostate carcinomas without response to hormonal therapy.

  2000cites this paper
• Prognostic significance of beta-microseminoprotein mRNA expression in prostate cancer.

  1999cites this paper
• Prospects for the treatment of endocrine-responsive tumours.

  1999cites this paper
• Prognostic significance of β‐microseminoprotein mRNA expression in prostate cancer

  1999cites this paper
• p53 and bcl-2 immunohistochemistry in pretreatment prostate needle biopsies to predict recurrence of prostate cancer after radical prostatectomy.

  1999cites this paper
• Original Articles BCL-2 AND P53 EXPRESSION IN CLINICALLY LOCALIZED PROSTATE CANCER PREDICTS RESPONSE TO EXTERNAL BEAM RADIOTHERAPY

  1999cites this paper
• Prognostic markers in clinically localised prostate cancer.

  1999cites this paper
• Gemcitabine-Induced Programmed Cell Death (Apoptosis) of Human Pancreatic Carcinoma Is Determined by Bcl-2 Content

  1999cites this paper
• BCL-2 and p53 expression in clinically localized prostate cancer predicts response to external beam radiotherapy.

  1999cites this paper
• p53 Alteration in regional lymph node metastases from prostate carcinoma

  1999cites this paper
• Preoperative p53, bcl-2, CD44 and E-cadherin immunohistochemistry as predictors of biochemical relapse after radical prostatectomy.

  1999cites this paper
• Practical clinical application of predictive factors in prostate cancer. A review with an emphasis on quantitative methods in tissue specimens.

  1998cites this paper